scholarly journals Mitigation of Insulin Resistance by Mangiferin in a Rat Model of Fructose-Induced Metabolic Syndrome Is Associated with Modulation of CD36 Redistribution in the Skeletal Muscle

2015 ◽  
Vol 356 (1) ◽  
pp. 74-84 ◽  
Author(s):  
L. Zhou ◽  
Y. Pan ◽  
R. Chonan ◽  
R. Batey ◽  
X. Rong ◽  
...  
2010 ◽  
Vol 161 (2) ◽  
pp. 350-364 ◽  
Author(s):  
Cristina Contreras ◽  
Ana Sánchez ◽  
Pilar Martínez ◽  
Rafaela Raposo ◽  
Belén Climent ◽  
...  

2013 ◽  
Vol 98 (10) ◽  
pp. 1485-1494 ◽  
Author(s):  
Fleur Poelkens ◽  
Gerwen Lammers ◽  
Elisabeth M. Pardoel ◽  
Cees J. Tack ◽  
Maria T. E. Hopman

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Mohsen Fathzadeh ◽  
Ali Reza Keramati ◽  
Gwang Go ◽  
Rajvir Singh ◽  
Kazem Sarajzadeh ◽  
...  

We have identified a novel nonconservative mutation in Minibrain related serine/threonine kinase (Mirk/ Dyrk1B) in outlier kindreds with metabolic syndrome. The mutation substitutes cysteine for arginine (R102C) and segregates with most traits of metabolic syndrome, including central obesity, diabetes and hypertension. Oral glucose tolerance test (OGTT) in young nondiabetic mutation carriers revealed insulin resistance compared to noncarrier family members. Since skeletal muscle (SM) is the largest organ for glucose uptake and metabolism, we obtained Vastus Lateralis biopsies of mutation carriers and their unaffected relatives and examined them for gene/protein expression by deep RNA sequencing (RNA-Seq) and Western blot analysis and for fiber composition by immunostaining. The fiber composition data demonstrated fewer slow-twitch fibers (35% vs. 75%) and more fast -twitch fibers (65% vs. 25%) in SM of mutation carriers vs. controls. Interestingly, there were increased protein expression levels of fast-twitch fiber type proteins (MYH11, MYLPF), pyruvate dehydrogenase kinase, pyruvate kinase, and neuronal nitric oxide synthase in SM of mutation carriers vs. noncarriers. Consistent with these findings, the protein expression levels of the master regulator of cellular energy metabolism mitochondrial biogenesis, PPAR-gamma coactivator (PGC-1a), were reduced and the nuclear expression levels of FOXO1 and NFAT were increased. Similar findings were observed when wildtype and mutant (R102C) Dyrk1B were overexpressed in C2C12 cells. The overexpression of the kinase deficient Dyrk1B (Y271/273F) similarly resulted in reduced expression of PGC-1a and increased expression of nuclear FOXO1, suggesting kinase independent effects. Taken together, these findings suggest that enhanced kinase-independent activities of Dyrk1B, either through increased expression or by its gain of function mutation R102C induce insulin resistance by promoting glycolytic metabolism and reducing oxidative phosphorylation. In conclusion, Dyrk1B is a potential target for development of novel drugs that aim to enhance skeletal muscle insulin sensitivity.


2020 ◽  
Vol 21 (14) ◽  
pp. 4860 ◽  
Author(s):  
Michele Mannelli ◽  
Tania Gamberi ◽  
Francesca Magherini ◽  
Tania Fiaschi

Cachexia is a devastating pathology induced by several kinds of diseases, including cancer. The hallmark of cancer cachexia is an extended weight loss mainly due to skeletal muscle wasting and fat storage depletion from adipose tissue. The latter exerts key functions for the health of the whole organism, also through the secretion of several adipokines. These hormones induce a plethora of effects in target tissues, ranging from metabolic to differentiating ones. Conversely, the decrease of the circulating level of several adipokines positively correlates with insulin resistance, metabolic syndrome, diabetes, and cardiovascular disease. A lot of findings suggest that cancer cachexia is associated with changed secretion of adipokines by adipose tissue. In agreement, cachectic patients show often altered circulating levels of adipokines. This review reported the findings of adipokines (leptin, adiponectin, resistin, apelin, and visfatin) in cancer cachexia, highlighting that to study in-depth the involvement of these hormones in this pathology could lead to the development of new therapeutic strategies.


2012 ◽  
Vol 224 (2) ◽  
pp. 377-383 ◽  
Author(s):  
Sang-Hyun Ihm ◽  
Sung-Won Jang ◽  
Ok-Ran Kim ◽  
Kiyuk Chang ◽  
Min-Ho Oak ◽  
...  

2010 ◽  
Vol 106 (10) ◽  
pp. 1550-1554 ◽  
Author(s):  
Akinori Iba ◽  
Yasuo Kohjimoto ◽  
Takashi Mori ◽  
Tomomi Kuramoto ◽  
Satoshi Nishizawa ◽  
...  

FEBS Letters ◽  
2007 ◽  
Vol 581 (29) ◽  
pp. 5664-5670 ◽  
Author(s):  
Michiyo Deushi ◽  
Mitsunori Nomura ◽  
Akio Kawakami ◽  
Mihoko Haraguchi ◽  
Mizuho Ito ◽  
...  

2006 ◽  
Vol 291 (6) ◽  
pp. E1341-E1350 ◽  
Author(s):  
Sarah M. Turpin ◽  
Graeme I. Lancaster ◽  
Ian Darby ◽  
Mark A. Febbraio ◽  
Matthew J. Watt

Fatty acid-induced apoptosis occurs in pancreatic β-cells and contributes to the metabolic syndrome. Skeletal muscle insulin resistance is mediated by fatty acid oversupply, which also contributes to the metabolic syndrome. Therefore, we examined whether fatty acids induce apoptosis in skeletal muscle myotubes, the proapoptotic signaling involved, and the effects on insulin sensitivity. Exposure of L6 myotubes to palmitate induced apoptosis, as demonstrated by increased caspase-3 activation, phosphatidylserine exposure on the plasma membrane, and terminal deoxynucleotide transferase dUTP nick end labeling and DNA laddering, both markers of DNA fragmentation. Ceramide content was concomitantly increased, indicating a potential role for ceramides in palmitate-induced apoptosis. Supporting this notion, reducing stearoyl-CoA desaturase-1 (SCD-1) protein content with short interfering RNA resulted in ceramide accumulation and was associated with increased apoptosis in the absence of palmitate. Furthermore, the membrane-permeable C2-ceramide enhanced apoptosis in myotubes, whereas the ceramide synthase inhibitor, fumonisin B1, abrogated the proapoptotic effects of palmitate. Insulin-stimulated glucose uptake was inhibited by palmitate treatment, whereas the addition of effector caspase inhibitors [Ac-DEVD-aldehyde (DEVD-CHO), Z-DQMD-FMK] independently restored >80% of the insulin-stimulated glucose uptake. These effects were observed independently from changes in the protein content of insulin signaling proteins, suggesting that proteosomal degradation is not involved in this process. We conclude that lipoapoptosis occurs in skeletal muscle myotubes, at least partially via de novo ceramide accumulation, and that inhibiting downstream apoptotic signaling improves glucose uptake in vitro.


Sign in / Sign up

Export Citation Format

Share Document